News Conference News EAS 2022 ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News EAS 2022 Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News EAS 2021 Central and Eastern Europe Failing to Achieve LDL Treatment Targets: DA VINCI Michael O'Riordan June 07, 2021
News Conference News EAS 2021 Lp(a) Not Associated With Ongoing Aortic Valve Calcification Michael O'Riordan June 04, 2021
News Conference News EAS 2019 CHD Mortality Significantly Elevated in Patients With Severe FH Michael O'Riordan May 29, 2019
News Conference News EAS 2019 Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis Michael O'Riordan May 28, 2019
News Conference News EAS 2018 Glucose and Beyond? Experts Debate Optimal Targets for Managing CV Risk in Diabetics Yael L. Maxwell May 16, 2018
News Conference News EAS 2018 ORION 1 Data Show Lipoprotein-Lowering Beyond LDL Cholesterol With Injectable Inclisiran Yael L. Maxwell May 14, 2018
News Conference News EAS 2018 Can Clinicians Really Put a Stop to Atherosclerosis? Experts Explore the How and When of CVD Prevention Yael L. Maxwell May 07, 2018
News Conference News EAS 2018 Biology in the Back Seat: EAS 2018 Opens With Calls for a Big-Picture Approach to CVD Prevention Yael L. Maxwell May 07, 2018